 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12...13141516171819202122232425» |
- | Prevymis (letermovir) / Merck (MSD)
Journal: A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation. (Pubmed Central) - Jan 8, 2021
P3
Letermovir may reduce mortality by preventing or delaying CS-CMVi in HCT recipients.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Pubmed Central) - Jan 6, 2021
The detected incidence of CMV resistance among subjects who received LET as prophylaxis in this Phase 3 trial was low. The LET RAVs that were detected mapped to the CMV UL56 gene at positions associated with reduced susceptibility to LET based on resistance selections in cell culture.
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: ... pts without #BMT benefits, selecting vori vs posa based on copay, pts cannot get letermovir since OOP $$$ is unaffordable (and they don’t qualify for manufacturer grant program) etc etc (Twitter) - Jan 4, 2021
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Cytomegalovirus infection in hematopoietic stem cell transplant patients before and after initiation of a high risk prophylaxis protocol with letermovir () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3742;
The LET RAVs that were detected mapped to the CMV UL56 gene at positions associated with reduced susceptibility to LET based on resistance selections in cell culture. N/A
- Prevymis (letermovir) / Merck (MSD), Envarsus (LCP-Tacro) / Asahi Kasei
[VIRTUAL] Effect of letermovir for prophylaxis of cytomegalovirus on extended release tacrolimus levels in a kidney transplant patient () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3177;
Overall, the dose required a decrease of 47 percent in order to successfully reach the normal tacrolimus trough range. According to this data, the dose change required for Envarsus® differs from that of Prograf® and shows that the dose adjustments made for immediate release tacrolimus are not the same as the extended release tacrolimus.
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
[VIRTUAL] Real-World Usage and Clinical Outcomes Associated with Letermovir in Allogeneic HCT Patients at High Risk for CMV Reactivation () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1632;
This reduction in CMV reactivation occurred despite the larger proportion of high risk patients in the letermovir group. All-cause mortality at 48 weeks did not significantly differ between letermovir and pre-emptive therapy groups, even after adjustment for confounding factors.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Medication Regimen Complexity Index Over Time in Allogeneic Hematopoietic Cell Transplantation Patients Receiving Letermovir Prophylaxis or Pre-emptive Therapy () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1536;
Although there was an initial increase in MRCI between letermovir and pre-emptive therapy groups at day +100, this increase was transient. By 1-year post-HCT, MRCI values were significantly lower for letermovir recipients versus those who received pre-emptive therapy, despite the higher proportion of high risk patients in the letermovir group.
- || Foscavir (foscarnet) / Pfizer, Clinigen, Cytovene (ganciclovir) / Roche
Review, Journal: Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. (Pubmed Central) - Dec 23, 2020
Maribavir, an inhibitor of the CMV UL97 kinase, is currently in two phase 3 treatment studies...Vaccine development continues, with several promising candidates currently under study. No longer limited to DNA polymerase inhibitors, the prevention and treatment of CMV infections in the HCT recipient is a rapidly evolving field which should translate into improvements in CMV-related outcomes.
- Prevymis (letermovir) / Merck (MSD), Vocozo (voriconazole) / Orchid
[VIRTUAL] Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients () - Dec 20, 2020 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_489;
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Cytomegalovirus Reactivation in Allogeneic Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis and Cytomegalovirus Specific T Cell Immunity, a Retrospective Single Center Experience () - Dec 20, 2020 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_332;
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Letermovir Resistance in Hematopoietic Stem Cell Transplant Recipients: The Risks Associated with Cytomegalovirus Prophylaxis. (Pubmed Central) - Dec 18, 2020
No longer limited to DNA polymerase inhibitors, the prevention and treatment of CMV infections in the HCT recipient is a rapidly evolving field which should translate into improvements in CMV-related outcomes. No abstract available
- |||| Clinical: #Letermovir is not approved for treatment of active #CMV infection, so they would not be part of this trial. These were patients with active #CMV refractory (still viremic without decrease in VL) with our without documented resistance to ganciclovir, foscarnet or cidofovir (Twitter) - Dec 4, 2020
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: Did they have any letermovir resistant/ failure patients? (Twitter) - Dec 4, 2020
- || Prevymis (letermovir) / Merck (MSD)
Review, Journal, IO Biomarker: Potential Therapeutic Approaches Against Brain Diseases Associated with Cytomegalovirus Infections. (Pubmed Central) - Dec 1, 2020
Fortunately, letermovir which targets the HCMV terminase complex rather than DNA polymerase with fewer adverse reactions has been approved to treat CMV infections in humans...For the treatment of glioblastoma, vaccine therapy through targeting specific CMV antigens has improved patients' survival outcomes significantly and immunotherapy has also emerged as an alternative modality. The advanced research for developing anti-CMV agents and approaches is promising to obtain significant outcomes and expecting to have a great impact on the therapy of brain diseases associated with CMV infections.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Advances in CMV Management: A Single Center Real-Life Experience. (Pubmed Central) - Nov 18, 2020
Moreover, CMV DNAemia at the time of PET in the 12 patients with a clinically significant CMV infection was higher in WB vs. PL (5.202 vs. 4.981 copies/ml, p = 0.1). Our real-life experience confirms that: (i) letermovir is highly effective, leading to a significant drop in CMV clinically significant infections and CMV-related complications by day + 100 and + 180 after allo-SCT; (ii) WB may be an effective alternative to PL as a source for CMV DNA monitoring, as a linear correlation of DNAemia was confirmed between WB and PL, even if the CMV DNAemia at PET initiation was comparable in the two sources.
- |||| Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
Clinical: NEW 🔥🔥 #CID @IDSAInfo @HannahImlay Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. #IDTwitter Cc @UMIntMed @FranciscoMarty_ https://t.co/bMBvFxOwui (Twitter) - Nov 16, 2020
- | Prevymis (letermovir) / Merck (MSD)
Journal: Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation. (Pubmed Central) - Nov 6, 2020
Our real-life experience confirms that: (i) letermovir is highly effective, leading to a significant drop in CMV clinically significant infections and CMV-related complications by day + 100 and + 180 after allo-SCT; (ii) WB may be an effective alternative to PL as a source for CMV DNA monitoring, as a linear correlation of DNAemia was confirmed between WB and PL, even if the CMV DNAemia at PET initiation was comparable in the two sources. No abstract available
- | Prevymis (letermovir) / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection (clinicaltrials.gov) - Nov 6, 2020
P2, N=86, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
No abstract available Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Real-World Experience Using Letermovir for CMV Prophylaxis in High-Risk Allogeneic Hematopoietic Stem Cell Patients in the Setting of Using T-Cell Depletion As Gvhd Prophylaxis and the Impact on CMV Reactivation, 1-Year Overall Survival, and 1-Year Gvhd-Free-Relapse-Free Survival () - Nov 5, 2020 - Abstract #ASH2020ASH_5459;
51% were male and 49% were female. The donor sources comprised of 27% match related, 28% match-unrelated, and 49% haplo-identical.
- Prevymis (letermovir) / Merck (MSD), Vocozo (voriconazole) / Orchid
[VIRTUAL] Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients () - Nov 5, 2020 - Abstract #ASH2020ASH_4950;
Notably, patients receiving the 300 mg dose upfront may not require an additional dose increase to achieve a voriconazole trough within the recommended range despite the concomitant use of letermovir. Our group is collaborating with other centers to corroborate these findings, particularly in patients receiving the standard voriconazole prophylactic dose of 200 mg.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4091;
CMV reactivation had no significant impact on HSCT outcomes. Our findings may help to identify a group of patients who could benefit from closer monitoring and possibly primary prophylaxis with novel agents, such as letermovir.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Vaccination of Hematopoietic Stem Cell (HCT) Donors with Triplex, a Novel Cytomegalovirus Vaccine: Safety, Feasibility and Adoptive Transfer of Protective CMV-Specific T Cells in HCT Recipients (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1289;
P2
The approach is feasible and highly tolerable, with promising evidence of efficacy, indicating that Triplex vaccination of the MRD confers early protective anti-CMV immunity to the HCT recipient. Clinical and immunological outcomes from the ongoing study indicate that this novel immune therapeutic strategy provides a safer alternative to antivirals, including letermovir prophylaxis and may find application in higher CMV risk patients, such as haploidentical HCT recipients.
- tacrolimus / Generic mfg., sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1269;
Together, this knowledge of epidemiology and resource utilization may be used to inform preventive strategies to minimize CMVi, e.g., use of antiviral agent letermovir...Most commonly used graft-versus-host disease prophylaxis consisted of post-transplant cyclophosphamide (100%), Tacrolimus/sirolimus (83%), and cyclosporine/cellcept (78%) in Haplo, MUD, and CB-HCT recipients, respectively...CMVi during primary HCT admission was associated with significantly higher health care resource utilization; longer hospital LOS and supportive care utilization (CMV specific antiviral usage, transfusion and growth factors use). Prophylactic strategies to prevent early CMVi in alloHCT should be considered to decrease NRM and improve value based care delivery.
- valacyclovir / Generic mfg.
[VIRTUAL] High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1266;
Prophylactic ganciclovir or valganciclovir are challenging due to myelotoxicity...CMV infection following high dose VALA cessation remains a risk, particularly when dose reductions have occurred due to toxicity, and intolerance and ongoing monitoring is required. Treatment tolerability remains a limitation.
- || Prevymis (letermovir) / Merck (MSD)
Can you elaborate? You’re using high dose letermovir for treatment of CMV viremia or you don’t see breakthrough viremia on suppressive dose letermovir? (Twitter) - Nov 4, 2020
- | Prevymis (letermovir) / Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Journal: Quantification of letermovir in human serum using high-performance liquid chromatography with diode array detection. (Pubmed Central) - Oct 31, 2020
Precision expressed as coefficient of variation was 1.44-3.15% (intra-day) and 1.17-1.93% (inter-day). The method was successfully applied for analysis of 128 letermovir levels demonstrating its usefulness for letermovir monitoring in routine clinical practice.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Determination of Letermovir Serum Levels Can Be Useful in High-Risk Clinical Settings. (Pubmed Central) - Oct 24, 2020
The method was successfully applied for analysis of 128 letermovir levels demonstrating its usefulness for letermovir monitoring in routine clinical practice. No abstract available
- || Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
Clinical, Journal: Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient. (Pubmed Central) - Oct 24, 2020
No abstract available No abstract available
- |||| Prevymis (letermovir) / Merck (MSD)
Clinical: Bottom line Letermovir 💊 is highly effective👍🏻@ASH_hematology #IDtwitter @ASTCT Letermovir for prevention of CMV in haplo and mismatched adult donor allogeneic HSCT w PTCY https://t.co/iZdRd6Ldg8 (Twitter) - Oct 11, 2020
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study. (Pubmed Central) - Oct 8, 2020
No abstract available Despite the development of better approaches with weekly monitoring and early treatment initiation, CMV reactivations play an important role after allo-HSCT.
- | Prevymis (letermovir) / Merck (MSD)
Journal: Highlighting of a LAGLIDADG and a Zing Finger Motifs Located in the pUL56 Sequence Crucial for HCMV Replication. (Pubmed Central) - Oct 7, 2020
These patterns are crucial for viral replication, suggesting that they are essential for pUL56 structure and function. Thus, these patterns represent potential targets for the development of new antivirals such as small molecules or peptides and may allow to better understand the letermovir mechanism of action.
- | Prevymis (letermovir) / Merck (MSD)
Journal: Palladium-Catalyzed Asymmetric Allylic C-H Functionalization: Mechanism, Stereo- and Regioselectivities, and Synthetic Applications. (Pubmed Central) - Oct 4, 2020
In particular, the asymmetric allylic C-H alkylation of 1,4-dienes with azlactones offers highly enantioenriched α,α-disubstituted α-amino acid derivatives that are capable of serving as key building blocks for the enantioselective synthesis of lepadiformine alkaloids. In addition, a tachykinin receptor antagonist and (-)-tanikolide are also synthesized with chiral molecules generated from the corresponding allylic C-H alkylation reactions.
- | Prevymis (letermovir) / Merck (MSD)
Journal: The terminase complex, a relevant target for the treatment of HCMV infection (Pubmed Central) - Oct 3, 2020
A new terminase inhibitor, letermovir, recently proved effective against HCMV in phase III clinical trials. However, its mechanism of action is unclear and it has no significant activity against other herpesvirus or non-human CMV.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: A Fine Balance: Using Letermovir For Salvage Antiviral Treatment While Preserving Efficacy. (Pubmed Central) - Oct 1, 2020
However, its mechanism of action is unclear and it has no significant activity against other herpesvirus or non-human CMV. No abstract available
- || Prevymis (letermovir) / Merck (MSD), tacrolimus / Generic mfg.
Clinical, Journal: Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipients. (Pubmed Central) - Oct 1, 2020
CMV-infection and -disease were successfully managed with letermovir. Letermovir was well tolerated and effective in treating CMV-infections in lung transplant recipients failing on currently available antiviral agents.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. (Pubmed Central) - Oct 1, 2020
Letermovir was well tolerated and effective in treating CMV-infections in lung transplant recipients failing on currently available antiviral agents. We demonstrate mixed efficacy in patients with refractory CMV infection suggesting that letermovir may be a useful therapeutic adjunct, potentially in combination with other antivirals.
- || Prevymis (letermovir) / Merck (MSD)
Review, Journal: Antiviral Agents as Therapeutic Strategies Against Cytomegalovirus Infections. (Pubmed Central) - Sep 30, 2020
Fortunately, letermovir which targets the human CMV (HCMV) terminase complex has been recently approved to treat CMV infections in humans...Additionally, adoptive T cell therapy (ACT) has been experimentally used to combate drug-resistant and recurrent CMV in patients after cell and/or organ transplantation. Developing antiviral agents is promising in this area to obtain fruitful outcomes and to have a great impact on humans for the therapy of CMV infections.
- | Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
Journal: Validation and characterization of five distinct novel inhibitors of human cytomegalovirus. (Pubmed Central) - Sep 26, 2020
Drug combination studies revealed that all five compounds were additive with ganciclovir or letermovir. Future studies will determine the potential for development of these new compounds as anti-HCMV drugs and their use as probes to study virus-host interaction.
- ||| Prevymis (letermovir) / Merck (MSD)
Then beyond that, letermovir in SOT? It’s only in poster form though. Then there’s a battery of new HIV drugs if you’re game? ;) (Twitter) - Sep 24, 2020
- | Prevymis (letermovir) / Merck (MSD)
Trial completion date, Trial primary completion date, Post-transplantation: Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) (clinicaltrials.gov) - Sep 22, 2020
P3, N=216, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Future studies will determine the potential for development of these new compounds as anti-HCMV drugs and their use as probes to study virus-host interaction. Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Aug 2021 --> Jan 2022
- | Prevymis (letermovir) / Merck (MSD), acyclovir / Generic mfg.
Journal: DNA Encapsidation and Capsid Assembly Are Underexploited Antiviral Targets for the Treatment of Herpesviruses. (Pubmed Central) - Sep 11, 2020
Acyclovir is the drug of choice for HSV encephalopathy, yet there is an estimated 6-19% mortality rate with half of the survivors experiencing moderate to severe chronic neurological deficits...Drug resistance is a concern for HCMV, HSV, and VZV since approved drugs share common mechanisms of action. Targeting DNA encapsidation or capsid assembly provide additional options for the development of non-nucleoside, small molecule anti-herpesviral drugs.
- | Prevymis (letermovir) / Merck (MSD)
Trial completion date, Trial primary completion date: Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) (clinicaltrials.gov) - Sep 11, 2020
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Targeting DNA encapsidation or capsid assembly provide additional options for the development of non-nucleoside, small molecule anti-herpesviral drugs. Trial completion date: Sep 2021 --> Aug 2022 | Trial primary completion date: Sep 2021 --> Aug 2022
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Combinatorial Polyfunctionality Analysis of Antigen-specific T-cell Subsets (COMPASS) as a Predictor for Clinically Significant CMV Infection in the Letermovir Era (On Demand) - Sep 10, 2020 - Abstract #IDWeek2020IDWEEK_2608;
Our findings demonstrate that COMPASS is a valuable tool to evaluate multiple, T-cell cytokine responses to CMV in HCT recipients. COMPASS appears to be useful to identify patients at risk for late cs-CMV infection.
- |||| Prevymis (letermovir) / Merck (MSD)
Clinical: Thank you for talking to us! Interesting to see the journey of finding a successful anti-CMV therapy in HSCT. Now we have letermovir, I wonder about its use in prophylaxis in other groups of immunosuppressed patients.. (Twitter) - Sep 3, 2020
- [VIRTUAL] Treatment of a patient with severe CMV reactivation after allo-HSCT with CMV-specific T cells from an external donor after failure of conventional antiviral therapy (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2009;
On d+65, the patient developed steroid-refractory grade III GvHD, mainly of the gut, which improved with the start of ruxolitinib...We treated her with ganciclovir and, for lack of response, with foscarnet without sufficient response... Adoptive CMV-specific T cell transfer from unrelated third-party donors is a feasible and effective method for the treatment of resistant CMV-viremia after allo-HSCT in patients with an inadequate response to regular treatment.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Incidence of CMV replications and the role of letermovir in primary / secondary prophylaxis in the early phase after allogeneic haematopoietic stem cell transplantation (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1999;
Despite better approaches with weekly monitoring and early treatment initiation, CMV reactivations play an important role after allo-HSCT. New anti-viral strategies such as prophylaxis with letermovir for CMV may avoid CMV disease in high-risk patients and thus improve outcome.
- [VIRTUAL] Treatment of a patient with severe CMV reactivation after allo-HSCT with CMV-specific T cells from an external donor after failure of conventional antiviral therapy (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1292;
On d+65, the patient developed steroid-refractory grade III GvHD, mainly of the gut, which improved with the start of ruxolitinib...We treated her with ganciclovir and, for lack of response, with foscarnet without sufficient response... Adoptive CMV-specific T cell transfer from unrelated third-party donors is a feasible and effective method for the treatment of resistant CMV-viremia after allo-HSCT in patients with an inadequate response to regular treatment.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Incidence of CMV replications and the role of letermovir in primary / secondary prophylaxis in the early phase after allogeneic haematopoietic stem cell transplantation (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1282;
Despite better approaches with weekly monitoring and early treatment initiation, CMV reactivations play an important role after allo-HSCT. New anti-viral strategies such as prophylaxis with letermovir for CMV may avoid CMV disease in high-risk patients and thus improve outcome.
- [VIRTUAL] Treatment of a patient with severe CMV reactivation after allo-HSCT with CMV-specific T cells from an external donor after failure of conventional antiviral therapy (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_482;
On d+65, the patient developed steroid-refractory grade III GvHD, mainly of the gut, which improved with the start of ruxolitinib...We treated her with ganciclovir and, for lack of response, with foscarnet without sufficient response... Adoptive CMV-specific T cell transfer from unrelated third-party donors is a feasible and effective method for the treatment of resistant CMV-viremia after allo-HSCT in patients with an inadequate response to regular treatment.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Incidence of CMV replications and the role of letermovir in primary / secondary prophylaxis in the early phase after allogeneic haematopoietic stem cell transplantation (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_472;
Despite better approaches with weekly monitoring and early treatment initiation, CMV reactivations play an important role after allo-HSCT. New anti-viral strategies such as prophylaxis with letermovir for CMV may avoid CMV disease in high-risk patients and thus improve outcome.